TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Integrativ Biomedicin Öckerman AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
46
|
42 | |
| Financial expenses |
0
|
0 | |
| Earnings before taxes |
20
|
-3 | |
| EBITDA |
11
|
-12 | |
| Total assets |
66
|
64 | |
| Current assets |
64
|
61 | |
| Current liabilities |
4
|
2 | |
| Equity capital |
61
|
61 | |
| - share capital |
9
|
9 | |
| Employees (average) |
1
|
1
|
1 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
92.4%
|
95.3% | |
| Turnover per employee |
46
|
42 | |
| Profit as a percentage of turnover |
43.5%
|
-7.1% | |
| Return on assets (ROA) |
30.3%
|
-4.7% | |
| Current ratio |
1600%
|
3050.0% | |
| Return on equity (ROE) |
32.8%
|
-4.9% | |
| Change turnover |
4
|
-2 | |
| Change turnover % |
-17%
|
9%
|
-4% |
| Chg. No. of employees |
0
|
0
|
1 |
| Chg. No. of employees % |
0%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.